VEGFA and retinopathy of prematurity: The observational studies [15, 17, 22, 36, 44, 47, 52–55] that compared neurodevelopmental outcomes between intravitreal anti-VEGF and LPC for TR-ROP were of moderate or serious overall risk of bias and found many similarities between the two treatment modalities, while in case a significant difference existed, LPC had the better results in terms of neurodevelopmental outcomes (Table 5).